46184Whole genome sequencing of liquid biopsies to predict doxorubicin response in ovarian cancerClosedCollaborative R&DISCFPinpoint Oncology is developing new genetic tests on DNA from tumours to take the guesswork out of treating the deadliest cancers. We use machine learning to find patterns in tumour DNA which can be used to predict a person's response to cancer drugs. Our current test uses a biopsy of a patient's tumour to predict if they will respond to a drug used to treat ovarian cancer. In this project we want to see if we can use the same test on a patient's blood sample, rather than a tissue sample. If successful, this will be less invasive for the patient, safer, more convenient, and will reduce the cost of the test.